DS
FULC icon

David Shaw’s Fulcrum Therapeutics FULC Stock Holding History

David Shaw’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
3,044,385
+1,421,104
+88% +$8.64M 0.01% 1722
2026
Q1 		$12.5M Sell
1,623,281
-290,474
-15% -$2.69M 0.01% 1462
2025
Q4 		$21.6M Buy
1,913,755
+464,332
+32% +$4.73M 0.01% 1209
2025
Q3 		$13.3M Buy
1,449,423
+272,712
+23% +$1.97M 0.01% 1459
2025
Q2 		$8.1M Buy
1,176,711
+596,050
+103% +$3.19M 0.01% 1661
2025
Q1 		$1.67M Sell
580,661
-2,542
-0.4% -$9.34K ﹤0.01% 2735
2024
Q4 		$2.74M Sell
583,203
-174,528
-23% -$644K ﹤0.01% 2474
2024
Q3 		$2.71M Buy
757,731
+165,946
+28% +$1.23M ﹤0.01% 2458
2024
Q2 		$3.67M Sell
591,785
-33,391
-5% -$253K ﹤0.01% 2095
2024
Q1 		$5.9M Buy
625,176
+127,497
+26% +$1.14M 0.01% 1765
2023
Q4 		$3.36M Buy
497,679
+276,415
+125% +$1.23M ﹤0.01% 2250
2023
Q3 		$982K Buy
221,264
+75,042
+51% +$328K ﹤0.01% 3072
2023
Q2 		$483K Buy
146,222
+130,899
+854% +$385K ﹤0.01% 3438
2023
Q1 		$43.7K Sell
15,323
-160,823
-91% -$1.44M ﹤0.01% 4055
2022
Q4 		$1.28M Buy
176,146
+93,807
+114% +$612K ﹤0.01% 3273
2022
Q3 		$666K Sell
82,339
-57,143
-41% -$409K ﹤0.01% 3866
2022
Q2 		$683K Sell
139,482
-407,922
-75% -$3.99M ﹤0.01% 3882
2022
Q1 		$12.9M Sell
547,404
-304,744
-36% -$4.31M 0.01% 1369
2021
Q4 		$15.1M Buy
852,148
+54,047
+7% +$1.07M 0.01% 1301
2021
Q3 		$22.5M Buy
+798,101
New +$15.1M 0.02% 949

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

David Shaw's FULC Position: Q2 2026 in Review

David Shaw increased its Fulcrum Therapeutics (FULC) stake by 88% in Q2 2026, buying an estimated $8.64M and bringing the position to 3,044,385 shares worth $11.1M. The position accounts for 0.01% of the portfolio, ranked #1722.

David Shaw first reported a position in FULC in Q3 2021 and has held it in 20 quarters since. The position peaked at $22.5M in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • David Shaw held 3,044,385 shares of Fulcrum Therapeutics worth $11.1M as of Q2 2026.
  • David Shaw bought 1,421,104 Fulcrum Therapeutics shares in Q2 2026, an estimated $8.64M.
  • Fulcrum Therapeutics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1722 holding.
  • David Shaw first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • David Shaw's Fulcrum Therapeutics position peaked at $22.5M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.